Navigation Links
Dosing for RVX-208 Phase 1a Clinical Study Completed
Date:4/22/2008

Phase 1a study objectives were met

TSX Exchange Symbol: RVX

CALGARY, April 22 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead drug candidate, RVX-208, which addresses the dyslipidemia market. "Initial results from the emerging data are very good," declared Donald J. McCaffrey, President & CEO of Resverlogix. "As reported earlier this year the most remarkable results from this study continue to be the outstanding pharmacokinetics (drugability) of RVX-208. With these successful results in hand we are now planning for our Phase 1b/2a trial which, pending discussions and approval from the FDA, we expect to start later this year."

The primary objectives of the Phase 1a trial were to examine the safety, tolerability and pharmacokinetics of RVX-208. This study successfully met those objectives. In addition to the completed Phase 1a human clinical trial, RVX-208 has been the subject of 126 preclinical studies to date, comprising safety, toxicity, pharmacokinetics and pharmacology studies. The Company has selected the dosages to be used in the 28-day Phase 1b/2a study.

"We are very pleased with these promising results which indicate that RVX-208 is a safe and well tolerated drug," stated Dr. Jan Johansson, MD, PhD, Senior Vice President Medical Affairs of Resverlogix. "We are in the process of finalizing the tables, figures and legends for this past study." A review of the pharmacokinetic data was recently presented at the Arteriosclerosis, Thrombosis and Vascular Biology conference in Atlanta, GA.

About Cardiovascular Disease (CVD)

CVD can be generally defined as any abnormal condition characterized by dysfunction of the heart and blood vessels. CVD includes atherosclerosis (especially coronary heart disease which can lead to heart
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
2. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
6. Immucor CEOs Italian Trial Moves Toward Second Phase
7. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
11. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Sodium ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... China Acetic Acid Industry" is a professional and ... and Global Acetic Acid Market. The report ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... HARBOR, Mich. , Sept. 18, 2014  Health Enhancement ... biotech firm investigating early-stage algae bioactive compounds and metabolic processes, ... to the company,s board of directors. Ms. Nola E. ... and investment advisor joined the board effective September 17, 2014. ... Ms. Masterson agree to join our board," states Andrew ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... ... Inc. 5000 , ... Boston, MA (PRWEB) August 13, 2009 -- Inc. magazine announced on Wednesday its 2009 ... a diversified technology solutions company and a leader in web-database solutions, healthcare intelligence and ...
... National Physical Laboratory (NPL) in Teddington have developed imaging technology ... minimise wastage and solve an impending labour shortage for UK ... to 60% - which can mean up to 100,000 of ... farmers who were consulted during research. Falling number of migrant ...
... , , OMAHA, Neb., Aug. ... the quarter ended June 30, 2009. The Company,s financial results are presented in ... , The Company reported a net loss of $730,000 or $0.01 per ... $101,000 or $0.00 per share for the second quarter of 2008. , ...
Cached Biology Technology:Massachusetts Technology Corporation Named to Inc. 5000 List of Fastest Growing Private Companies 2UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year 2Transgenomic, Inc. Reports Second Quarter 2009 Results 2Transgenomic, Inc. Reports Second Quarter 2009 Results 3Transgenomic, Inc. Reports Second Quarter 2009 Results 4Transgenomic, Inc. Reports Second Quarter 2009 Results 5Transgenomic, Inc. Reports Second Quarter 2009 Results 6Transgenomic, Inc. Reports Second Quarter 2009 Results 7Transgenomic, Inc. Reports Second Quarter 2009 Results 8
(Date:9/18/2014)... 2014 -- Arizona turned its newborn screening program into a ... months, earning it the first-ever Newborn Screening Quality Award from ... presented Will Humble, M.P.H., Arizona,s Department of Health Services director, ... Humble established a policy of full transparency for the length ... samples to the lab for analysis, and set a target ...
(Date:9/18/2014)... rabbitfish which have devastated algal forests in the eastern ... Mediterranean basin if their distribution continues to expand as ... by an international team of researchers led by Dr ... of the Mediterranean Institute for Advanced Studies in Spain, ... Members of the team surveyed more than 1000 kilometres ...
(Date:9/18/2014)... the fish world, are the ideal animal in which ... moved from the ocean into tens of thousands of ... changing their skeleton to adapt to the new environment. ... sticklebacks now have turned up one of the genes ... change in that gene,s regulation in a freshwater population ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Tropical fish a threat to Mediterranean Sea ecosystems 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3
... collaboration with the Technical University of Braunschweig (TUBS), Germany ... autonomous unmanned aerial vehicles (UAVs) in Antarctica. This is ... in the Antarctic and the successful flights open up ... the harshest and remotest environment on Earth. Dr ...
... study, researchers taking advantage of improvements in satellite sensor ... of pollution from East Asian forest fires, urban exhaust, ... North America. China, the worlds most populated country, ... urban areas, and considerable expansion in automobile use over ...
... Human diseases and social networks would seem to ... of these two lies a network,communities within the ... In a recent paper in Physical Review E ... computer science and engineering and of genetics, and ...
Cached Biology News:Unmanned aerial vehicles mark robotic first for British Antarctic Survey 2NASA satellite measures pollution from east Asia to North America 2NASA satellite measures pollution from east Asia to North America 3Algorithm finds the network -- for genes or the Internet 2Algorithm finds the network -- for genes or the Internet 3
... polyclonal to ErbB 2 - BSA ... for all tested applications). ... conjugated to KLH, corresponding to C ... c-ErbB2 Entrez GeneID: ...
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
Biology Products: